Improving the Quality of Cryopreserved Ovarian Tissue Reimplantation Using Platelet-enriched Autologous Plasma
Recruiting now · Not applicable
Conditions studied: Cryopreservation, Ovary Injury, Infertility, Female, Menopause Ovarian Failure
In brief
The study is aimed to evaluate the effects of intraovarian injection of autologous Platelet-enriched Autologous Plasma on the outcomes of orthotopic transplantation of cryopreserved ovarian tissue.
Key facts
- Study ID
- NCT06261658
- Run by
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
- People needed
- 45
- Starts
- 2024-03-01
- Expected to finish
- 2033-12-29
- Last updated by the study team
- 2024-02-15
Who can join
Age: any. Sex: female. Healthy volunteers: not accepted.
You may qualify if…
- request for cryopreserved ovarian tissue transplantation;
- premature ovarian failure or irregular mentrual cycles;
- negative test for HIV, HBV, HCV, Treponema pallidum;
- negative PAP test;
- oncological authorization;
- absence of neoplastic contamination in the cryopreserved ovarian tissue;
- Informed consent
You may not qualify if…
- neoplastic contamination in cryopreserved ovarian tissue;
- history of endometriosis;
- endocrinological disorders present and not treated (uncompensated thyroid dysfunction, diabetes (type 1, type 2);
- body mass index (BMI) >30 kg/m2;
- circulating platelet level < 150,000 / mml;
- bacterial infection;
- ongoing use of anticoagulants;
- bleeding diathesis.
Where it is running
- Diego Raimondo — Bologna, BO, Italy (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.